风湿免疫科指南

订阅

MedSci主页 / 所有栏目 / 风湿免疫科指南

2018 欧洲共识建议：川崎病的诊断和治疗

2018-12-07 国外风湿免疫科相关专家小组 Rheumatology (Oxford). 2018 Dec 7.

川崎病

川崎病（Kawasaki diseaes）是一种以全身血管炎变为主要病理的急性发热性出疹性小儿疾病。本文主要诊断川崎病的诊断，评估和治疗提出了相应的指导意见。

中文标题：

2018 欧洲共识建议：川崎病的诊断和治疗

英文标题：

European consensus-based recommendations for the diagnosis and treatment of Kawasaki disease - the SHARE initiative.

发布机构：

国外风湿免疫科相关专家小组

发布日期：

2018-12-07

简要介绍：

川崎病（Kawasaki diseaes）是一种以全身血管炎变为主要病理的急性发热性出疹性小儿疾病。本文主要诊断川崎病的诊断，评估和治疗提出了相应的指导意见。 

,拓展指南：与川崎病相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=2018 欧洲共识建议：川崎病的诊断和治疗)] GetToolGuiderByIdResponse(projectId=1, id=8eb861c0016e71f1, title=2018 欧洲共识建议：川崎病的诊断和治疗, enTitle=European consensus-based recommendations for the diagnosis and treatment of Kawasaki disease - the SHARE initiative., guiderFrom=Rheumatology (Oxford). 2018 Dec 7., authorId=null, author=, summary=川崎病（Kawasaki diseaes）是一种以全身血管炎变为主要病理的急性发热性出疹性小儿疾病。本文主要诊断川崎病的诊断，评估和治疗提出了相应的指导意见。 , cover=, journalId=null, articlesId=null, associationId=893, associationName=国外风湿免疫科相关专家小组, associationIntro=null, copyright=0, guiderPublishedTime=Fri Dec 07 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<div>川崎病（Kawasaki diseaes）是一种以全身血管炎变为主要病理的急性发热性出疹性小儿疾病。本文主要诊断川崎病的诊断，评估和治疗提出了相应的指导意见。 </div> <div><br> </div>,拓展指南：<strong>与<font color=red>川崎病</font>相关指南：</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=776391c001a08921" title="2017 AHA科学声明：川崎病的诊断，治疗和长期管理" target=_blank>2017 AHA科学声明：川崎病的诊断，治疗和长期管理</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=15a131c001113ada" title="日本川崎病心血管后遗症诊断和管理指南（JCS 2013）" target=_blank>日本川崎病心血管后遗症诊断和管理指南（JCS 2013）</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=9feef1c0009362fa" title="2012 川崎病冠状动脉病变的临床处理建议" target=_blank>2012 川崎病冠状动脉病变的临床处理建议</a></li> 更多信息请点击：<a href="http://www.medsci.cn/guideline/list.do?q=%E5%B7%9D%E5%B4%8E%E7%97%85" target=_blank>有关川崎病更多指南</a></ul>, tagList=[TagDto(tagId=9477, tagName=川崎病)], categoryList=[CategoryDto(categoryId=15, categoryName=风湿免疫科, tenant=100), CategoryDto(categoryId=18, categoryName=儿科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=2, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=11168, appHits=1021, showAppHits=21, pcHits=7257, showPcHits=4457, likes=131, shares=38, comments=9, approvalStatus=1, publishedTime=Tue Dec 18 22:05:56 CST 2018, publishedTimeString=2018-12-07, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Tue Dec 18 22:05:56 CST 2018, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 15:41:36 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2018 欧洲共识建议：川崎病的诊断和治疗)])
2018 欧洲共识建议：川崎病的诊断和治疗
下载请点击：
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1080588, encodeId=8fff1080588e9, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=453c1494628, createdName=jyzoe1988, createdTime=Thu Dec 16 09:18:20 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976859, encodeId=7d369e6859f2, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ab1c1357927, createdName=563032036, createdTime=Fri Jun 25 18:55:45 CST 2021, time=2021-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960344, encodeId=7ba59603446d, content=想看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7985486060, createdName=ms6000000578788158, createdTime=Sun Apr 25 13:03:00 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960343, encodeId=3cf0960343ce, content=想看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7985486060, createdName=ms6000000578788158, createdTime=Sun Apr 25 13:01:08 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948954, encodeId=d43994895409, content=很有收获, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b1185121622, createdName=14638626m36暂无昵称, createdTime=Wed Mar 17 10:58:42 CST 2021, time=2021-03-17, status=1, ipAttribution=)]
    2021-12-16 jyzoe1988

    谢谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1080588, encodeId=8fff1080588e9, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=453c1494628, createdName=jyzoe1988, createdTime=Thu Dec 16 09:18:20 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976859, encodeId=7d369e6859f2, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ab1c1357927, createdName=563032036, createdTime=Fri Jun 25 18:55:45 CST 2021, time=2021-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960344, encodeId=7ba59603446d, content=想看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7985486060, createdName=ms6000000578788158, createdTime=Sun Apr 25 13:03:00 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960343, encodeId=3cf0960343ce, content=想看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7985486060, createdName=ms6000000578788158, createdTime=Sun Apr 25 13:01:08 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948954, encodeId=d43994895409, content=很有收获, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b1185121622, createdName=14638626m36暂无昵称, createdTime=Wed Mar 17 10:58:42 CST 2021, time=2021-03-17, status=1, ipAttribution=)]
    2021-06-25 563032036

    谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1080588, encodeId=8fff1080588e9, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=453c1494628, createdName=jyzoe1988, createdTime=Thu Dec 16 09:18:20 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976859, encodeId=7d369e6859f2, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ab1c1357927, createdName=563032036, createdTime=Fri Jun 25 18:55:45 CST 2021, time=2021-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960344, encodeId=7ba59603446d, content=想看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7985486060, createdName=ms6000000578788158, createdTime=Sun Apr 25 13:03:00 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960343, encodeId=3cf0960343ce, content=想看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7985486060, createdName=ms6000000578788158, createdTime=Sun Apr 25 13:01:08 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948954, encodeId=d43994895409, content=很有收获, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b1185121622, createdName=14638626m36暂无昵称, createdTime=Wed Mar 17 10:58:42 CST 2021, time=2021-03-17, status=1, ipAttribution=)]
    2021-04-25 ms6000000578788158

    想看

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1080588, encodeId=8fff1080588e9, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=453c1494628, createdName=jyzoe1988, createdTime=Thu Dec 16 09:18:20 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976859, encodeId=7d369e6859f2, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ab1c1357927, createdName=563032036, createdTime=Fri Jun 25 18:55:45 CST 2021, time=2021-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960344, encodeId=7ba59603446d, content=想看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7985486060, createdName=ms6000000578788158, createdTime=Sun Apr 25 13:03:00 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960343, encodeId=3cf0960343ce, content=想看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7985486060, createdName=ms6000000578788158, createdTime=Sun Apr 25 13:01:08 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948954, encodeId=d43994895409, content=很有收获, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b1185121622, createdName=14638626m36暂无昵称, createdTime=Wed Mar 17 10:58:42 CST 2021, time=2021-03-17, status=1, ipAttribution=)]
    2021-04-25 ms6000000578788158

    想看

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1080588, encodeId=8fff1080588e9, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=453c1494628, createdName=jyzoe1988, createdTime=Thu Dec 16 09:18:20 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976859, encodeId=7d369e6859f2, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ab1c1357927, createdName=563032036, createdTime=Fri Jun 25 18:55:45 CST 2021, time=2021-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960344, encodeId=7ba59603446d, content=想看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7985486060, createdName=ms6000000578788158, createdTime=Sun Apr 25 13:03:00 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960343, encodeId=3cf0960343ce, content=想看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7985486060, createdName=ms6000000578788158, createdTime=Sun Apr 25 13:01:08 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948954, encodeId=d43994895409, content=很有收获, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b1185121622, createdName=14638626m36暂无昵称, createdTime=Wed Mar 17 10:58:42 CST 2021, time=2021-03-17, status=1, ipAttribution=)]
    2021-03-17 14638626m36暂无昵称

    很有收获

    0

相关指南

2017 AHA科学声明：川崎病的诊断，治疗和长期管理

美国心脏病学会(ACC,American College of Cardiology) · 2017-03-29

日本川崎病心血管后遗症诊断和管理指南（JCS 2013）

日本循环学会(JCS,Japanese Circulation Society) · 2014-09-22

2012 川崎病冠状动脉病变的临床处理建议

中华医学会儿科学分会心血管学组 · 2012-10-01